Alambic Investment Management L.P. increased its position in Natus Medical Incorporated (NASDAQ:BABY) by 45.7% during the third quarter, Holdings Channel reports. The fund owned 18,800 shares of the company’s stock after buying an additional 5,900 shares during the period. Alambic Investment Management L.P. owned 0.06% of Natus Medical worth $739,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the company. Great West Life Assurance Co. Can boosted its stake in shares of Natus Medical by 1.7% in the third quarter. Great West Life Assurance Co. Can now owns 44,494 shares of the company’s stock worth $1,748,000 after buying an additional 752 shares during the last quarter. Henderson Group PLC boosted its stake in shares of Natus Medical by 33.6% in the third quarter. Henderson Group PLC now owns 496,295 shares of the company’s stock worth $19,499,000 after buying an additional 124,769 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Natus Medical by 44.1% in the third quarter. Nationwide Fund Advisors now owns 202,031 shares of the company’s stock worth $7,938,000 after buying an additional 61,811 shares during the last quarter. 1st Global Advisors Inc. bought a new stake in shares of Natus Medical during the third quarter worth approximately $283,000. Finally, Moody Aldrich Partners LLC boosted its stake in shares of Natus Medical by 10.0% in the third quarter. Moody Aldrich Partners LLC now owns 38,235 shares of the company’s stock worth $1,502,000 after buying an additional 3,475 shares during the last quarter. Institutional investors and hedge funds own 83.94% of the company’s stock.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Natus Medical Incorporated (NASDAQ:BABY) traded up 2.24% during mid-day trading on Friday, hitting $38.75. The company had a trading volume of 352,479 shares. The company has a 50-day moving average price of $37.71 and a 200 day moving average price of $39.28. Natus Medical Incorporated has a 12 month low of $29.54 and a 12 month high of $44.39. The firm has a market capitalization of $1.26 billion, a P/E ratio of 31.50 and a beta of 1.10.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, October 19th. The company reported $0.39 EPS for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.05. Natus Medical had a return on equity of 13.53% and a net margin of 10.89%. The company earned $90.90 million during the quarter, compared to analysts’ expectations of $89.94 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The firm’s revenue was down 3.9% compared to the same quarter last year. Equities analysts forecast that Natus Medical Incorporated will post $1.64 EPS for the current fiscal year.

WARNING: This piece of content was first reported by Watch List News and is the propert of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece of content can be viewed at http://www.watchlistnews.com/alambic-investment-management-l-p-purchases-5900-shares-of-natus-medical-incorporated-baby/1061586.html.

A number of analysts have commented on the company. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research report on Wednesday. Off Wall Street assumed coverage on Natus Medical in a research report on Friday, December 16th. They issued a “sell” rating for the company. Finally, Benchmark Co. assumed coverage on Natus Medical in a research report on Tuesday, October 4th. They issued a “buy” rating and a $55.00 price target for the company. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $45.25.

In other news, insider James B. Hawkins acquired 10,000 shares of the business’s stock in a transaction on Friday, December 16th. The stock was bought at an average cost of $35.20 per share, for a total transaction of $352,000.00. Following the purchase, the insider now owns 477,396 shares in the company, valued at $16,804,339.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert A. Gunst sold 3,250 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $41.92, for a total value of $136,240.00. Following the sale, the director now owns 51,150 shares of the company’s stock, valued at $2,144,208. The disclosure for this sale can be found here. 4.80% of the stock is owned by corporate insiders.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

5 Day Chart for NASDAQ:BABY

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.